Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 820 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR First treatment approved in England for advanced bile duct cancer July 22, 2021 EMA Recommends Extension of Indications for Olaparib September 24, 2020 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? April 19, 2019 Load more HOT NEWS Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer News digest – ovarian cancer blood test, statins, spending review and... More Than One in 10 Patients With Lung Cancer Do Not... Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe...
